1 Zhao X, Pan X, Wang Y, Zhang Y. Targeting neoantigens for cancer immunotherapy. Biomark Res 9: 61 (2021).
2 Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39: 1-10 (2013).
3 Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181: 799-804 (1995).
4 Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184: 2207-2216 (1996).
5 Bakker AB, Schreurs MW, de Boer AJ et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179: 1005-1009 (1994).
6 Rezaei T, Davoudian E, Khalili S et al. Strategies in DNA vaccine for melanoma cancer. Pigment Cell Melanoma Res 34: 869-891 (2021).
7 Yamano T, Kaneda Y, Huang S, Hiramatsu SH, Hoon DS. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol Ther 13: 194-202 (2006).
8 Yan J, Tingey C, Lyde R et al. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model. Cancer Gene Ther 21: 507-517 (2014).
9 Rossignol A, Bonnaudet V, Clemenceau B, Vie H, Bretaudeau L. A high-performance, non-radioactive potency assay for measuring cytotoxicity: A full substitute of the chromium-release assay targeting the regulatory-compliance objective. MAbs 9: 521-535 (2017).
10 Flieger D, Gruber R, Schlimok G, Reiter C, Pantel K, Riethmuller G. A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells. J Immunol Methods 180: 1-13 (1995).
11 Sheehy ME, McDermott AB, Furlan SN, Klenerman P, Nixon DF. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 249: 99-110 (2001).
12 Fischer K, Mackensen A. The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity. Methods 31: 135-142 (2003).
13 Luker GD, Luker KE. Luciferase protein complementation assays for bioluminescence imaging of cells and mice. Methods Mol Biol 680: 29-43 (2011).
14 Cheng Z, Garvin D, Paguio A, Stecha P, Wood K, Fan F. Luciferase Reporter Assay System for Deciphering GPCR Pathways. Curr Chem Genomics 4: 84-91 (2010).
15 Nishizawa H, Kurowarabe K, Hayashi R, Hayasaka H. Real-time monitoring of B16 melanoma cell viability by the firefly luciferase-based bioluminescence. Science and technology: 5-11. https://cir.nii.ac.jp/crid/1520572360409358336 (2021).
16 Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 61: 1095-1099 (2001).
17 Merritt RE, Yamada RE, Crystal RG, Korst RJ. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy. J Thorac Cardiovasc Surg 127: 355-364 (2004).
18 Nagato T, Lee YR, Harabuchi Y, Celis E. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res 20: 1223-1234 (2014).
19 Fu X, Tao L, Rivera A et al. A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS One 5: e11867 (2010).
20 Olivo Pimentel V, Yaromina A, Marcus D, Dubois LJ, Lambin P. A novel co-culture assay to assess anti-tumor CD8+ T cell cytotoxicity via luminescence and multicolor flow cytometry. J Immunol Methods 487: 112899 (2020).
21 Qi S, Shi H, Liu L, Zhou L, Zhang Z. Dynamic visualization of the whole process of cytotoxic T lymphocytes killing B16 tumor cells in vitro. J Biomed Opt 24: 1-7 (2019).
22 Glass-Marmor L, Penso J, Beitner R. Ca2+-induced changes in energy metabolism and viability of melanoma cells. Br J Cancer 81: 219-224 (1999).
23 Schlapbach R, Fontana A. Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycin-induced apoptosis of glioma cells. Biochim Biophys Acta 1359: 174-180 (1997).